Ghent University Academic Bibliography

Advanced

Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study

P Michielsen, E Bottieau, Hans Van Vlierberghe UGent, E Van Marck, E Vandemaele, M Denys, JP Brasseur, M Popan and Belgian Assoc Study Liver (2009) ACTA GASTRO-ENTEROLOGICA BELGICA. 72(4). p.389-393
abstract
Background and study aims : In Belgium, 10-15% of patients infected with the human immunodeficiency virus (HIV) are coinfected with hepatitis C virus (HCV). Because of increased incidence of antiretroviral drug-related hepatotoxicity and more rapid clinical evolution towards end-stage liver disease, treatment of chronic hepatitis C becomes a priority. We report the results or a multi-centred Belgian study evaluating efficacy and safety of peginterferon alpha-2b plus ribavirin in HIV-HCV co-infected patients without AIDS and without decompensated liver disease. Patients and methods : Forty-one patients, all genotypes, were screened to participate. Eventually 37 received treatment with peginterferon alpha-2b (1.5 mu g/kg/week) plus daily weight-based ribavirin for 52 weeks. About one third of the patients were genotypes 1, 2/3, and genotype 4, most of the latter being of Central African origin. About 56% of the patients had severe fibrosis (Metavir score >= F3). Results : Sustained viral response (SVR) at 24 weeks of follow-up was observed in 10/37 (27%) of patients. SVR was higher in genotype 2/3 compared to genotype 1/4 (46.7% versus 13.6%; p = 0.06) and in low (F0-F1) versus high (F2-F4) grade fibrosis (p = 0.06). Treatment was withdrawn for side effects in 11/37 patients (30%). One Child A cirrhosis patient at the start of therapy died 7 months after treatment withdrawal as a result of severe haemolytic anaemia. Conclusions : It can be concluded that weight-based peginterferon alpha-2b plus ribavirin can be successful in selected HIV-HCV co-infected patients. Caution should be applied in patients with advanced liver disease. (Acta gastroenterol. belg., 2009, 72, 389-393).
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
PEGYLATED INTERFERON-ALPHA-2B, INFECTED PATIENTS, COINFECTED PATIENTS, HCV/HIV-COINFECTION, THERAPY, TRIAL, GENOTYPE-4
journal title
ACTA GASTRO-ENTEROLOGICA BELGICA
Acta Gastro-Enterol. Belg
volume
72
issue
4
pages
389 - 393
Web of Science type
Article
Web of Science id
000273799600001
JCR category
GASTROENTEROLOGY & HEPATOLOGY
JCR impact factor
1.01 (2009)
JCR rank
54/64 (2009)
JCR quartile
4 (2009)
ISSN
0001-5644
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1003108
handle
http://hdl.handle.net/1854/LU-1003108
date created
2010-07-06 09:49:03
date last changed
2016-12-19 15:42:12
@article{1003108,
  abstract     = {Background and study aims : In Belgium, 10-15\% of patients infected with the human immunodeficiency virus (HIV) are coinfected with hepatitis C virus (HCV). Because of increased incidence of antiretroviral drug-related hepatotoxicity and more rapid clinical evolution towards end-stage liver disease, treatment of chronic hepatitis C becomes a priority. We report the results or a multi-centred Belgian study evaluating efficacy and safety of peginterferon alpha-2b plus ribavirin in HIV-HCV co-infected patients without AIDS and without decompensated liver disease.
Patients and methods : Forty-one patients, all genotypes, were screened to participate. Eventually 37 received treatment with peginterferon alpha-2b (1.5 mu g/kg/week) plus daily weight-based ribavirin for 52 weeks. About one third of the patients were genotypes 1, 2/3, and genotype 4, most of the latter being of Central African origin. About 56\% of the patients had severe fibrosis (Metavir score {\textrangle}= F3).
Results : Sustained viral response (SVR) at 24 weeks of follow-up was observed in 10/37 (27\%) of patients. SVR was higher in genotype 2/3 compared to genotype 1/4 (46.7\% versus 13.6\%; p = 0.06) and in low (F0-F1) versus high (F2-F4) grade fibrosis (p = 0.06). Treatment was withdrawn for side effects in 11/37 patients (30\%). One Child A cirrhosis patient at the start of therapy died 7 months after treatment withdrawal as a result of severe haemolytic anaemia.
Conclusions : It can be concluded that weight-based peginterferon alpha-2b plus ribavirin can be successful in selected HIV-HCV co-infected patients. Caution should be applied in patients with advanced liver disease. (Acta gastroenterol. belg., 2009, 72, 389-393).},
  author       = {Michielsen, P and Bottieau, E and Van Vlierberghe, Hans and Van Marck, E and Vandemaele, E and Denys, M and Brasseur, JP and Popan, M and Assoc Study Liver, Belgian},
  issn         = {0001-5644},
  journal      = {ACTA GASTRO-ENTEROLOGICA BELGICA},
  keyword      = {PEGYLATED INTERFERON-ALPHA-2B,INFECTED PATIENTS,COINFECTED PATIENTS,HCV/HIV-COINFECTION,THERAPY,TRIAL,GENOTYPE-4},
  language     = {eng},
  number       = {4},
  pages        = {389--393},
  title        = {Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study},
  volume       = {72},
  year         = {2009},
}

Chicago
Michielsen, P, E Bottieau, Hans Van Vlierberghe, E Van Marck, E Vandemaele, M Denys, JP Brasseur, M Popan, and Belgian Assoc Study Liver. 2009. “Treatment of Chronic Hepatitis C in Patients with Human Immunodeficiency Virus (HIV) with Weekly Peginterferon Alpha-2b Plus Ribavirin: a Multi-centred Belgian Study.” Acta Gastro-enterologica Belgica 72 (4): 389–393.
APA
Michielsen, P., Bottieau, E., Van Vlierberghe, H., Van Marck, E., Vandemaele, E., Denys, M., Brasseur, J., et al. (2009). Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study. ACTA GASTRO-ENTEROLOGICA BELGICA, 72(4), 389–393.
Vancouver
1.
Michielsen P, Bottieau E, Van Vlierberghe H, Van Marck E, Vandemaele E, Denys M, et al. Treatment of chronic hepatitis C in patients with human immunodeficiency virus (HIV) with weekly peginterferon alpha-2b plus ribavirin: a multi-centred Belgian study. ACTA GASTRO-ENTEROLOGICA BELGICA. 2009;72(4):389–93.
MLA
Michielsen, P, E Bottieau, Hans Van Vlierberghe, et al. “Treatment of Chronic Hepatitis C in Patients with Human Immunodeficiency Virus (HIV) with Weekly Peginterferon Alpha-2b Plus Ribavirin: a Multi-centred Belgian Study.” ACTA GASTRO-ENTEROLOGICA BELGICA 72.4 (2009): 389–393. Print.